Intravaginal ring

• US 4,292,965 A
• Filed: 12/29/1978
• Issued: 10/06/1981
• Est. Priority Date: 12/29/1978
• Status: Expired due to Term

• Current Assignee: Population Council Inc.
• Original Assignee: Population Council Inc.
• Inventors: Nash, Harold A., Mishell, Daniel R. Jr.
• Primary Examiner(s): Michell, Robert W.
• Assistant Examiner(s): ROSENBAUM, C FRED
• Application Number:
  US05/974,490
• Time in Patent Office: 1,012 Days
• Field of Search: 128/127, 128/130, 128/172, 128/260, 128/261, 128/271, 424/16, 424/19, 424/22, 427/2, 427/430 R, 427/402, 427/413, 427/434 R, 427/434 D, 427/434 E
• US Class Current: 128/833
• CPC Class Codes: A61F 6/08 Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception , e.g. combined with devices protecting against contagion
• CPC Class Codes: A61K 9/0036 Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms

Abstract

This invention relates to an improved intravaginal ring for use as a contraceptive comprising an inert elastomer core, a medicated layer encircling the core and an outer inert elastomer layer and method of manufacturing the intravaginal ring.

Claims

1. A shell design intravaginal ring comprising in combination a core made of an inert elastomer, a medicated layer encircling the core, and an outer inert elastomer layer having a thickness of about 0.1 to 0.6 mm, the medicated layer comprising an inert elastomer and a combination of estradiol with a progestogen selected from the group consisting of levonorgestrel, d,l-norgestrel and norethindrone and the medicated layer having a thickness of not more than twice the thickness of the outer layer.

2. The intravaginal ring described in claim 1 wherein the progesten is levonorgestrel and the outer layer is about 0.2 mm thick.

3. The intravaginal ring described in claim 1 wherein the inert elastomer is a polysiloxane.

4. The intravaginal ring as described in claim 1 wherein the inert elastomer is a polysiloxane, the medicated layer contains about 70 mg levonorgestrel and about 35 mg estradiol and the outer layer is about 0.2 mm thick.

5. The intravaginal ring as described in claim 4 wherein the medicated layer contains about 40-240 mg levonorgestrel and about 30-100 mg estradiol.

6. A method of contraception which comprises the steps of retainably positioning within the vaginal tract an intravaginal ring as defined in claim 1.

7. A method of contraception, which comprises the steps of retainably positioning within the vaginal tract an intravaginal ring as defined in claim 1 retaining the ring in place for an approximate three week period, and removing the ring for an approximate one week period to permit menstruation.

9. The method of manufacturing intravaginal rings as described in claim 1 wherein the progestogen is selected from the group consisting of levonorgestrel, d,l-norgestrel and norethindrone.

8. A method of manufacturing a shell design intravaginal ring which consists of:

(a) forming a core ring of a suitable inert elastomer;

(b) dipping the core ring in a mixture of an inert volatile solvent containing an inert unvulcanized elastomer and a mixture of estradiol and a progestogen to form a medicated layer;

(c) removing the ring from the mixture and allowing the solvent to evaporate;

(d) repeating steps b and c until a medicated layer of the desired thickness is obtained;

(e) dipping the ring from step d into a mixture of an inert unvulcanized elastomer in an inert volatile solvent removing the ring and allowing the solvent to evaporate to form an outer layer; and

(f) repeating step e until an outer layer of desired thickness is obtained.

10. A method of manufacturing a shell design intravaginal ring which consists of:

(a) forming an annular core ring of a suitable inert elastomer by injecting the unvulcanized elastomer into a mold and allowing the ring to cure in the mold;

(b) removing the core ring from the mold and cutting the ring open;

(c) bringing the open ring to a constant weight;

(d) pulling the open ring through a coating solution containing an unvulcanized elastomer and a mixture of estradiol and a progestogen;

(e) dipping the coated open ring in a catalyst solution and allowing the coating to polymerize;

(f) swelling a piece of tubing in volatile organic solvent and fitting it over the open ring from step e and allowing the solvent to evaporate;

(g) trimming the excess tubing from the ends of the open ring and applying a medical grade adhesive to the ends of the open ring and on the surface of the ring close to the open end;

(h) placing a piece of swollen tubing over both ends of the open ring to reform the ring and holding the ends of the open ring together for a few minutes and curing the ring for about 24 hours.

11. The method of manufacturing intravaginal rings as described in claim 10 wherein the progestogen is selected from the group consisting of levonorgestrel, d,l-norgestrel and norethindrone.

12. A method of manufacturing a shell design intravaginal ring which consists of:

(a) forming a core rod of suitable inert elastomer by injecting the unvulcanized elastomer into a mold and allowing it to cure;

(b) removing the resulting core rod and cutting it into lengths about 15.5 cm;

(c) bringing the rod to a constant weight;

(d) pulling the rod through a coating solution containing a mixture of an unvulcanized elastomer and a mixture of estradiol and a progestogen;

(e) dipping the coated rod in a catalyst solution and allowing the coating to polymerize;

(f) swelling a piece of tubing in a volatile organic solvent, and sliding it over the coated rod from step e and allowing the solvent to evaporate;

(g) trimming the excess tubing from the ends of the rod and applying a medical grade adhesive to the ends of the rod and to the surface of the rod close to the end;

(h) placing a second piece of swollen tubing over both ends of the rod to form a ring and holding the ends of the rod together for 24 hours until the adhesive has cured.

13. The method of manufacturing intravaginal rings as described in claim 12 wherein the progestogen is selected from the group consisting of levonorgestrel, d,l-norgestrel and norethindrone.